155 related articles for article (PubMed ID: 20972242)
1. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
2. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
[TBL] [Abstract][Full Text] [Related]
3. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Itamochi H; Kigawa J; Terakawa N
Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
7. Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo.
Umezu T; Shibata K; Shimaoka M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Senga T; Kikkawa F
Cancer Sci; 2010 Jan; 101(1):143-8. PubMed ID: 19860840
[TBL] [Abstract][Full Text] [Related]
8. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract][Full Text] [Related]
10. Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary.
Kajiyama H; Hosono S; Terauchi M; Shibata K; Ino K; Yamamoto E; Nomura S; Nawa A; Kikkawa F
Oncology; 2006; 71(5-6):394-401. PubMed ID: 17690559
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 expression in clear cell adenocarcinoma of the ovary.
Maeda D; Ota S; Takazawa Y; Aburatani H; Nakagawa S; Yano T; Taketani Y; Kodama T; Fukayama M
Mod Pathol; 2009 Jun; 22(6):824-32. PubMed ID: 19329941
[TBL] [Abstract][Full Text] [Related]
13. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.
Itamochi H; Oumi N; Oishi T; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Clin Oncol; 2015 Oct; 20(5):967-73. PubMed ID: 25744580
[TBL] [Abstract][Full Text] [Related]
14. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
[TBL] [Abstract][Full Text] [Related]
16. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
Kandil DH; Cooper K
Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
[TBL] [Abstract][Full Text] [Related]
20. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]